Suspected progression of metastatic melanoma should always be confirmed by biopsy
and pathological examination. Indeed, many non-cancerous lesions can mimic metastases
and lead to inappropriate management of patients in the absence of histology. This
can be particularly true in the context of certain therapeutic backgrounds associated
with bone vulnerability such as chronic treatment with the antiretroviral drug tenofovir
as illustrated in this patient's case where a suspicion of bone metastasis was rectified
after bone biopsy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
PrEP-guidelines-2017.pdf [Internet]. [cited 2022 Sep 6]. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.
- Tenofovir and bone health.Curr Opin HIV AIDS [Internet]. 2016 May; 11 ([cited 2022 Sep 6];Available from:): 326-332
- Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey.PPA [Internet]. 2018 Oct; 12 ([cited 2022 Sep 6]; Available from:): 2197-2204
- The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.Antivir Ther [Internet]. 2020 Jan; 25 ([cited 2022 Sep 6]; Available from:): 21-32
- Changes in bone mineral density with age in men and women: a longitudinal study.Osteoporos Int [Internet]. 2002 Feb 1; 13 ([cited 2022 Sep 7]; Available from:): 105-112https://doi.org/10.1007/s001980200001
- Risedronate therapy prevents corticosteroid-induced bone loss : a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.Arthritis & Rheum [Internet]. 1999; 42 ([cited 2022 Sep 7]; Available from:): 2309-2318
Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Reviews. :10.
Article info
Publication history
Published online: January 24, 2023
Accepted:
December 31,
2022
Received:
December 26,
2022
Publication stage
In Press Uncorrected ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
